Medizinische Universität Graz - Research portal
Comprehensive Cancer Center Graz
Comprehensive Cancer Center Graz
SCI/PUBMED listed | all typs of publications | all by year and first author | MUG authors |
** = Publications listed in SCI/SSCI/Pubmed
Full paper/article (Journal)
** Ruznic, E; Klebermass, M; Zellinger, B; Langer, B; Grambozov, B; Purevdorj, A; Karner, J; Gruber, G; Stana, M; Minasch, D; Kirchhammer, K; Steffal, C; Stranzl, H; Moosbrugger, R; Feurstein, P; Dieckmann, K; Zehentmayr, F; ALLSTAR Grp
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
J CLIN MED. 2025; 14(3): 945
Doi: 10.3390/jcm14030945
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Wenzl, FA; Wang, P; Kahles, F; Beck, KR; Giannitsis, E; Obeid, S; Bruno, F; Li, XS; Nanchen, D; Liberale, L; Smolle, MA; Schweiger, V; Klingenberg, R; Manka, R; Stähli, BE; Templin, C; König, M; Yuan, J; Yildirim, M; Lehrke, M; von, Eckardstein, A; Marx, N; Mach, F; Räber, L; Katus, HA; Steinhagen-Thiessen, E; Demuth, I; Deanfield, J; Libby, P; Hazen, SL; Haghikia, A; Landmesser, U; Bäckhed, F; Lüscher, TF
Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.
Eur Heart J. 2025;
Doi: 10.1093/eurheartj/ehaf661
PubMed
FullText
FullText_MUG
Short report/Letter
** Smolle, MA; Wenzl, FA; Szkandera, J; Scheipl, S; Liegl-Atzwanger, B; Igrec, J; Leithner, A
Incidence of and survival with bone and soft tissue sarcoma: A nation-wide study over four decades.
Cancer Commun (Lond). 2025; 45(4):397-400
Doi: 10.1002/cac2.12653
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Dobri, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Lazzeri, I; Albertini, C; Rinnerthaler, G; Starzer, AM; Bartsch, R; Hasenleithner, SO; Jost, PJ; Heitzer, E; Balic, M
Circulating tumor DNA profiling of patients with metastatic luminal HER2-low and HER2-0 breast cancer via next-generation sequencing.
J CLIN ONCOL. 2025; 43(16_SUPPL): e13090-e13090.
Doi: 10.1200/JCO.2025.43.16_suppl.e13090
Web of Science
FullText
FullText_MUG